Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 5.3 GBX
Market Cap: 252.6m GBX
Have any thoughts about
Allergy Therapeutics PLC?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-7.1
Current
-3.6
Median
13.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-7.1
=
Enterprise Value
247.2m GBX
/
EBITDA
-34.6m GBP
All Countries
Close

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-8.2
2-Years Forward
EV/EBITDA
-13.6
3-Years Forward
EV/EBITDA
-55.8

See Also

Discover More